Table 2. Baseline demographic characteristics of 52 patients treated with lapatinib plus capecitabine.
Characteristic | No. of patients (%) |
Age (years) | |
Median | 50 |
Range | 26–71 |
Menopausal | 24 (46.2) |
Stage of disease | |
Stage IIIB/IIIC | 1 (1.9) |
Stage IV | 51 (98.1) |
Hormone receptor status | |
ER+ and/or PR+ | 25 (48.1) |
ER– and PR– | 26 (50.0) |
Unknown | 1 (1.9) |
ECOG PS | |
0 | 30 (57.7) |
1 | 22 (42.3) |
Metastatic sites | |
Visceral and/or nonvisceral | 41 (78.8) |
Nonvisceral only | 11 (21.2) |
Data are presented as number of patients, with the percentage in parentheses, except for age. ER+, estrogen receptor–positive; PR+, progesterone receptor–positive; ER–, estrogen receptor–negative; PR–, progesterone receptor–negative; ECOG, Eastern Cooperative Oncology Group; PS, performance status.